Clinical Trial Update: A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus [Phase 1]

View source ↗

Summary

A completed Phase 1 trial evaluating the safety of oral SRT2104 and its effects on vascular function in smokers and individuals with Type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SRT2104 (SRT2104)

Snippet

Sponsor: Sirtris, a GSK Company | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED